Prelude Therapeutics
Develops small-molecule oncology programs centered on JAK2V617F inhibition and KAT6A degradation.
$5.52
After-hours close+0.06 (+1.04%)
At close$5.47(−13.80%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 39.20%30.77M sharesInsiders 5.01%3.94M sharesOther 55.79%43.79M shares
Shares outstanding 78.50M · Float 41.76M · 53.2% free float
Institutions13F, as of Mar 31, 2026
56 holders · 30.77M shares · 13 new positions · 32 increased · 12 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Orbimed Advisors LLC | 10.91M | 13.90% | 0 | May 15, 2026 |
| Baker Bros. Advisors LP | 10.12M | 12.90% | 0 | May 15, 2026 |
| Kynam Capital Management, LP | 1.59M | 2.03% | +803.7K | May 15, 2026 |
| Vanguard Capital Management LLC | 1.23M | 1.57% | +1.23Mnew | May 15, 2026 |
| Ecor1 Capital, LLC | 947.0K | 1.21% | +947.0Knew | May 15, 2026 |
| Two Sigma Investments, LP | 923.6K | 1.18% | +134.9K | May 15, 2026 |
| Sphera Funds Management Ltd. | 558.3K | 0.71% | +435.6K | May 15, 2026 |
| Acadian Asset Management LLC | 511.5K | 0.65% | −24.2K | May 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Orbimed Advisors LLCincl. OrbiMed Genesis GP LLC, Orbimed Capital GP Vi LLC +1 more | 16.00% | 12.94M | 13D | Apr 23, 2026 ↗ |
| Baker Bros. Advisors (GP) LLCincl. Julian C. Baker, Baker Bros. Advisors LP +1 more | 15.50% | 10.30M | 13D | Apr 22, 2026 ↗ |
| Vaddi Krishna | 13.15% | 6.75M | 13G | Feb 13, 2026 ↗ |
| RA Capital Management, L.P. | 9.90% | 6.48M | 13G | Apr 28, 2026 ↗ |
| Incyte Corp | 9.90% | 4.37M | 13G | Nov 7, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 10 percent owner | 6.48M | 8.25% | Apr 28, 2026 |
| Krishna Vaddi | director, officer: CEO | 2.14M | 2.73% | Mar 27, 2025 |
| Orbimed Advisors LLC | director, 10 percent owner: | 1.13M | 1.43% | Apr 23, 2026 |
| Andrew Combs | officer: Chief Chemistry Officer | 480.1K | 0.61% | Mar 27, 2025 |
| Sean P. Brusky | officer: Chief Business Officer | 100.0K | 0.13% | Mar 19, 2026 |
| Jane Huang | officer: President, CMO | 86.9K | 0.11% | Oct 7, 2025 |
1 ten-percent owner holds 6.48M shares by Form 4 — the 13D/G table above shows that stake, the figure above counts officers and directors only · 9 people have not refiled in the last 18 months (11.35M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Apr 21, 2026 | Orbimed Advisors LLCdirector, 10 percent owner: | Purchase · 2 lots | 2,815,315 | $4.44 | 11,808,945 |
| Apr 21, 2026 | David P. Bonitadirector, 10 percent owner: | Purchase · 2 lots | 2,815,315 | $4.44 | 11,808,945 |
| Apr 21, 2026 | Baker Bros. Advisors LPdirector, 10 percent owner: | Purchase · 2 lots | 2,252,252 | $0.0001 | 20,105,994 |
CongressHouse and Senate disclosures
Not reported.